Moteur de recherche d’entreprises européennes
Financement de l’UE (17,7 M €) : Guide des thérapies multi-modales contre la MRD par biopsies liquides - GUIDE. MRD Hor01/05/2023 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Guide des thérapies multi-modales contre la MRD par biopsies liquides - GUIDE. MRD
Advancing personalized approaches in cancer therapy, aiding identification and adaptation of multi-modal treatment strategies for improved outcomes depends on clinical implementation of novel diagnostic technologies. For most cancer types the risk-features used to select individuals for post-operative adjuvant multimodal therapy are suboptimal, where many patients are overtreated and others undertreated. Liquid biopsy has opened a new diagnostic avenue to detect and monitor minimal residual disease (MRD) in individual cancer patients, especially for selecting patients for multi-modal therapies post-operatively. However, despite many circulating tumor DNA (ctDNA) diagnostics being developed there is a lack of standardization, harmonization, and robust data to demonstrate clinical validity. GUIDE.MRD is a consortium of leading academics, technology companies, pharmaceutical companies, and experts in multi-stakeholder engagements. Together, we will tackle the critical questions by developing reference standards for ctDNA diagnostics, clinically validate promising ctDNA diagnostics and develop data to guide the use of multi-modal therapies with a non-invasive diagnostic test. With robust engagement with regulatory authorities, payers and importantly patients themselves, we will develop recommendations and guidelines based on objective data to use ctDNA diagnostics to guide multi-modal therapy selection to improve patient outcomes.
| ABBVIE DEUTSCHLAND GmbH & Co. KG | ? |
| Aarhus Universitet | 1 142 500 € |
| Aarhus Universitetshospital | 2 701 344 € |
| ABBVIE Inc. | 0,00 € |
| ACADEMISCH ZIEKENHUIS GRONINGEN | 1 513 496 € |
| AMGEN (EUROPE) GmbH | 0,00 € |
| Asociatia Centrul Pentru Inovatie in Medicina | 276 250 € |
| Astrazeneca UK Ltd. | 0,00 € |
| BRISTOL-MYERS SQUIBB COMPANY Corp. | 0,00 € |
| Centre Hospitalier Universitaire de Nice | 719 625 € |
| Centre Hospitalier Universitaire Montpellier | 1 385 764 € |
| Digestive Cancers Europe Dice | 289 750 € |
| F. HOFFMANN-LA ROCHE AG | 0,00 € |
| Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos III | 1 272 889 € |
| Horizon Discovery Ltd. | 0,00 € |
| Illumina Cambridge Ltd. | 0,00 € |
| Innovation Acta Srl | 377 734 € |
| Karolinska Institutet | 655 138 € |
| LGC CLINICAL DIAGNOSTICS Inc. | 0,00 € |
| LUNGENCLINIC GROSSHANSDORF GmbH | 765 364 € |
| Medizinische Universitat Graz | 1 918 230 € |
| Region Stockholm | 853 336 € |
| Synergist Services | 842 716 € |
| THE Synergist | 600 901 € |
| UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF | 2 345 919 € |
https://cordis.europa.eu/project/id/101112066
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Allemagne.